# ACUTE CORONARY SYNDROME

#### Dr. Aniff YEAROO

- Term used for any condition brought on by sudden, reduced blood flow to the heart.
- Presentations variable chest pain Dyspnea to cardiac arrest
- ACS is treatable if diagnosed quickly is a complication of a plaque buildup in the Coronary Arteries (Coronary Atherosclerosis)
- Most are due to rupture of plaque and formation of a blood clot.

### **Risk factors**

- Age ≥45yrs
- HBP
- High cholesterol
- Cigarette smoking
- Lack of physical activity
- Type 2 diabetes
- Family history

### Diagnosis

- Electrocardiogram
- Blood Tests
- Cardiac Enzymes
- Echocardiography
- Coronary Angiogram

### Treatment

- Antithrombotic and dual antiplatelet therapy
  - Aspirin clopidogrel ticagrelor prasugrel GPIIb/IIIa inhibitors
- Fibrinolysis or Primary PCI
- Nitroglycerin
- Beta blocker
- Surgery

#### **Radial Access**

- Less bleeding complications
- RIVAL Register 7000 patients (1.4 vs 3.7%)
- STEMI RADIAL (2014) 707 patients
- 1.4% vascular complication versus
  7.2% (femoral)
  No mortality benefit

Manual Thrombus Aspiration (STEMI) TASTE STUDY – Randomized study – 7244 patients 30 days comparable MACE >TAPAS Registry 4212 patients (Sweden) MACE higher in thrombus aspiration patients -  $\uparrow$  mortality > Older studies – showed more benefits (REMEDIA) -  $\downarrow$  mortality one year Selection of patients important (Thrombus ++ )

**Multivessel Disease in ACS** Timing for complete Revascularization ➢ ESC 2012 – " Staged Procedure" – unless choc or persistent ischeamia > META ANALYSIS – (early 2014)  $\uparrow$  MACE for complete revascularization **Recent publications (awaiting further** studies) showed no significant MACE for complete Revascularization (Re hospitalisation-Reintervention)

### NSTEMI

- DAPT before Coronary Angiography
- > ABOARD ACCOAST
- 5-10% CABG
- 20-25% Medical (Distal Disease, Myocarditis, Pulmonary embolism, Dissection of the Aorta)
- Clopidogrel (P2Y12 inhibitor) effect in 12hours
- Newer drugs Prasugrel & Ticagrelor faster effect
- ESC DAPT as soon as possible Recent controversies in ACS (NSTEMI)
- Meta analysis 37814 patients
- Higher risk patients more beneficial (STEMI)– Newer drugs act quicker – Pre treatment needs re evaluation

ACCOAST STUDY (NSTEMI) 4033 patients – NSTEMI – PCI- Prasugrel

 No benefit for pre treatment (10% vs 9.8%)
 Pretreatment with prasugrel ↑Bleeding risk
 Prasugrel after Coronary Angiography
 No benefit in NSTEMI for early PCI

#### STEMI

PCI <2 hours after medical contact (otherwiseThrombolysis) (ESC Recommendation)

DAPT ASA + (Prasugrel C.I previous CVA, TIA, <75yrs, <60kgs)</li>
 + Ticagrelor (less MACE)

Clopidogrel second intention

#### Prasugrel – (TRITON – TIMI) vs Clopidogrel

- ↓ 19% MACE 15 months
- ↓ stent thrombosis 30 days 1.2 vs 2.4%
- > Ticagrelor ( PLATO) vs Clopidogrel
- ↓ MACE 16% one year




Figure 1. Registre REACH: risque d'AVC hémorragique non fatal à 4 ans de suivi (d'après [6]).




Figure 2. Mortalité intrahospitalière chez les patients SCA ST+ et SCA ST- en fonction du stade d'atteinte rénale (d'après [7]).




Figure 1. Étude ACCOAST : critère primaire : décès CV, IDM, AVC et revascularisation par anti-GPIIb/IIIa en urgence à 7 et à 30 jours (d'après [9]).




Figure 2. Étude ACCOAST : critère primaire de tolérance.




Figure 3. Critères principaux d'efficacité et de tolérance sur toute la durée de l'étude TRITON sur la population STEMI (d'après [2]).




Figure 4. Évolution du PRU chez des patients STEMI en cas d'administration de prasugrel ou de ticagrélor (d'après [4]).




Figure 1. Critère principal de l'étude STREAM.




Figure 2. Étude EUROMAX : critère principal – décès ou saignements majeurs à 30 jours (d'après [3]).

# CLINICAL CASE

- 50 years old man without any previous medical history presented with a six hours intermittent constricting chest pain
- ECG changes and troponine consistent with anterior NSTEMI
- Coronary Angiography revealed a double vessel disease. Tight LAD ( culprit lesion) and RCA disease
- LAD predilated BVS Absorb Post dilated
- RCA FFR 0.78 0.80 predilated and stented BVS